BRAF and melanoma: Approval in 2011 of the BRAF-inhibitor vemurafenib and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-antibody ipilimumab has resulted in significant improvements in the treatment of advanced melanoma.